The most advanced closed-system

fecal containment solution

QoraTM SMK is designed to provide bedridden patients and care providers with the

safest and most hygienic solution for fecal containment

QoraTM uses novel

self-positioning technology

to enable a simple, no-mess deployment.

1. INSERT
APPLICATOR INTO THE ANAL CANAL

2. RETRIEVE
APPLICATOR COMPONENTS

3. STOOL DIVERTER DEPLOYED
IN THE RECTUM

Advanced features of Qora TM make it

intuitive and user friendly

Zero Contact
hygienic deployment

Flatus Release Filter
for automatic odor-free degassing

User Friendly Packaging
for intuitive placement and management

Withdrawal Port
for timely and easy removal

Easily visible device-use reminders

Complete Malodor Protection

Sample Port
for stool sample collection

Irrigation Port
for flushing the device

Qora’s superior fecal containment

technology benefits bedridden

patients by
limiting risk of hospital

acquired infections

Everyday, patients present with a myriad of conditions
from ICUs to hospice care. Every care setting struggles to manage
diarrhea, but QoraTM has been engineered to protect patients and
caregivers regardless of their condition or location.

CDI

HEPATIC ENCEPHALOPATHY

KIDNEY & LIVER DISEASE

SEPTIC SHOCK

Clostridium difficile-associated
diarrhea / antibiotic-induced diarrhea

Hepatic encephalopathy (diarrhea
induced to resolve symptoms)

Kidney and liver disease (increase of
creatinine, blood urea, and nitrogen in
body resulting in diarrhea)

Septic shock (multi-organ failure)
leads to irritable bowel syndrome

CEREBRAL HAEMORRHAGE

SPINAL CORD INJURY

BURNS

Cerebral haemorrhage leads to
loss of neuromuscular control and
contributes to altered colonic motility
and liquid stool incontinence

Lower-limb / spinal cord injury leads to
prolonged bedridden states and makes
it difficult to manage fecal effluent in
traditional methods

Burns injury trauma and post-surgical
grafts must remain sterile for recovery;
risk of sepsis is very high

Backed by sound clinical evidence and an
experienced development team, Qora’s
global performance continues to demonstrate
outstanding safety & efficacy.

Patients with
multiple
co-morbidities
have the greatest
benefit from
decreased fecal
exposure

PERFORMANCE

Age, mean, years

Sex

Duration, mean, days

Devices reinsertions, mean

Stool consistency at withdrawal

Spontaneous expulsion

Balloon over-inflation

Peripheral diverter leakage

Anal atony

INTRARECTAL BALLOON CATHETERS

48.3-65.25

38%-73.7% (men)

5.6-17.4

1.17-1.4

Bristol 7 - 52%
Bristol 6 - 29%
Bristol 5 - 19%

20-28%

14%

Major - 4 to 13%
Minor - 53%
None - 29%

8-25 %

QoraTM SMK

54.7±17.3

73% (Men)

4.98 ± 4.89

1.09

Bristol 7 - 45%
Bristol 6 - 43%
Bristol 5 - 12%

12.77%

No Inflation Required

Major - 12%
Minor - 51%
None - 37%

0 %

Qora's USP

  • Effective across wide demographic
  • Used in patients 24-84 years of age and successful in conscious patients
  • Demonstrated functionality and safety through 29 days of use in multiple patients
  • Replacement required when stool consistency not managed or poor patient selection
  • QoraTM can be used in more patients as their stool consistency improves
  • Device has shown to successfully divert Bristol 5 stool types
  • Lower expulsion rates due to enhanced anatomical conformance and more comfortable diverter
  • Less management and risk of mucosal injury due to novel diverter design
  • Leakage rates contributed to first time users of any BMS
  • Majority of Minor leakage events resolved over length of use
  • Anatomical placement avoid atony